Drug Profile
Research programme: metabolic disorder therapeutics - AriBio
Alternative Names: AR-1008; AR-1009Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator AriBio
- Class Eye disorder therapies; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic complications; Diabetic retinopathy; Obesity
Most Recent Events
- 31 Dec 2020 Discontinued - Preclinical for Diabetic complications in South Korea (unspecified route), prior to December 2020 (AriBio pipeline, September 2023)
- 31 Dec 2020 Discontinued - Preclinical for Obesity in South Korea (unspecified route), prior to December 2020 (AriBio pipeline, September 2023)
- 31 Dec 2020 Discontinued for Diabetic retinopathy in South Korea (unspecified route), prior to December 2020 (AriBio pipeline, September 2023)